• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 8. Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Chemotherapy (No. of Cycles)aRadiation (Gy)No. of PatientsEvent-Free Survival (No. of Years of Follow-up)Survival (No. of Years of Follow-up)
COPP/ABV (4)b [23]None 5296% (5)100% (5)
IFRT (21)29100% (5)
CVP (3) [46]None5574% (5)100% (5)
VAMP (4)c [50]None 2687.5% (5)N/A
IFRT (25)6
VAMP (4) [42]IFRT (15–25.5)33100% (10)100% (10)
Noned [21] None 5167% (2)100% (2)
DBVE (2–4)c [44]None 26 94% (8)100% (8)
IFRT (25.5)

IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.

aRefer to Table 4 for more information about the chemotherapy regimens.

bAllocation to radiation therapy or no radiation therapy based on response to therapy.

cAllocation based on clinical response.

dAll involved lymph nodes surgically resected.

From: Childhood Hodgkin Lymphoma Treatment (PDQ®)

Cover of PDQ Cancer Information Summaries
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.